Group 1 - The Chinese Ministry of Commerce expressed a consistent and clear stance on the potential visit of a U.S. business delegation to China, emphasizing mutual respect and cooperation to enhance Sino-U.S. economic relations [2] - Siemens confirmed that the U.S. government has lifted the licensing requirements for exporting chip design software to China, allowing full access for Chinese customers to their software and technology [2] - The Ministry of Commerce reported that China's service trade grew steadily in the first five months of 2025, with total service trade reaching 32,543.6 billion yuan, a year-on-year increase of 7.7% [3] Group 2 - The Ministry of Industry and Information Technology held a meeting focusing on accelerating the high-quality development of the photovoltaic industry, addressing issues of low-price competition and promoting the exit of outdated capacity [3] - The Tianjin Municipal Government is soliciting opinions on a plan to enhance the development of new productivity through technology finance, aiming to support 300 companies in listing and establishing a reserve of 100 technology firms with listing potential [4] - Chinese scientists made a breakthrough in brain mapping research, successfully creating a three-dimensional brain region and stereotactic atlas with a resolution of 1 micron, providing a key tool for neuroscience [4] Group 3 - The National Medical Products Administration announced measures to optimize the lifecycle supervision of high-end medical devices, supporting the rapid market entry of innovative medical devices with significant clinical value [5] - The U.S. Department of Labor reported that the non-farm employment population in June increased by 147,000, significantly exceeding expectations, while the unemployment rate unexpectedly dropped to 4.1% [5] Group 4 - Li Lecheng, Minister of Industry and Information Technology, emphasized the need for comprehensive governance of the photovoltaic industry to promote sustainable development [3] - Huazhong Steel received a stake increase from Xintai Life Insurance, raising its holding to 5% [7] - China Merchants Bank has been approved to establish a financial asset investment company with a registered capital of 15 billion yuan [15]

Group 1 - The Ministry of Commerce reported that from January to May 2025, China's service trade grew steadily, with total service trade reaching 32,543.6 billion yuan, a year-on-year increase of 7.7%. Exports were 14,033.7 billion yuan, up 15.1%, while imports were 18,509.9 billion yuan, increasing by 2.7%. The service trade deficit was 4,476.2 billion yuan, a decrease of 1,352.2 billion yuan compared to the same period last year [2] - The Ministry of Industry and Information Technology held a meeting focusing on accelerating the high-quality development of the photovoltaic industry, emphasizing the need to address low-price disorderly competition and guide companies to improve product quality [2] - The Tianjin Municipal Government is seeking public opinion on the "Tianjin Science and Technology Finance Action Plan (2025-2027)", which aims to establish a regional equity market to support 300 companies and create a listing reserve of 100 technology companies [3] Group 2 - The National Medical Products Administration announced measures to optimize the lifecycle supervision of high-end medical devices, including special reviews for innovative medical devices with significant clinical value and support for products based on brain-computer interface technology [4] - Companies such as Liu Steel and Huazhong Steel are experiencing stock fluctuations, with Liu Steel facing potential irrational speculation risks and Huazhong Steel being acquired by a major shareholder [5] - Aerospace Morning Light has regained its qualification for military material engineering service procurement [6]

证券代码：688136 证券简称：科兴制药 公告编号：2025-046 科兴生物制药股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 科兴生物制药股份有限公司（以下简称"公司"）股票连续三个交易日 内（2025 年 7 月 1 日、7 月 2 日、7 月 3 日）收盘价格涨幅偏离值累计超过 30%， 属于股票交易异常波动。 经公司自查，并向公司控股股东、实际控制人进行书面询证，截至本公 告披露日，确认不存在关于公司的应披露而未披露的重大事项，公司日常经营情 况正常，未发生重大变化，所处的行业政策未发生重大调整。 公司股价短期波动幅度较大，公司特别提醒广大投资者，注意投资风险、 理性决策、审慎投资。 一、股票交易异常波动的具体情况 公司股票连续三个交易日内（2025 年 7 月 1 日、7 月 2 日、7 月 3 日）收盘 价格涨幅偏离值累计超过 30%，根据《上海证券交易所科创板股票异常交易实时 监控细则》的有关规定，属于股票交易异常波动的情形。 二、公司关注并核实的相关情况 ...

Market Performance - The Sci-Tech Innovation Board (STAR Market) index rose by 0.24%, closing at 984.95 points, with a total trading volume of 2.701 billion shares and a turnover of 90.146 billion yuan, resulting in a weighted average turnover rate of 1.52% [1] - Among the tradable stocks on the STAR Market, 365 stocks closed higher, with 5 stocks increasing by over 10% and 30 stocks rising between 5% and 10%. Conversely, 208 stocks closed lower [1] Turnover Rate Analysis - The distribution of turnover rates shows that 2 stocks had turnover rates exceeding 20%, 11 stocks had rates between 10% and 20%, 44 stocks had rates between 5% and 10%, 72 stocks had rates between 3% and 5%, 294 stocks had rates between 1% and 3%, and 165 stocks had rates below 1% [1] - The stock with the highest turnover rate was Xinyuren, which closed up by 4.80% with a turnover rate of 33.00% and a transaction amount of 594 million yuan. Huasheng Lithium Battery followed with a 15.36% increase and a turnover rate of 21.64% [1] Sector Performance - In terms of industry performance, the pharmaceutical and biotechnology sector had the most stocks with a turnover rate exceeding 5%, totaling 14 stocks. The electronics and power equipment sectors followed with 13 and 10 stocks, respectively [2] Capital Flow - Among the high turnover stocks, 34 stocks experienced net inflows of main funds, with the highest net inflows recorded for Bolite, Kexing Pharmaceutical, and Huiyu Pharmaceutical, amounting to 131 million yuan, 74.062 million yuan, and 60.026 million yuan, respectively [2] - Conversely, the stocks with the largest net outflows included Huicheng Co., Daqian Energy, and Sunshine Nuohe, with net outflows of 76.657 million yuan, 56.088 million yuan, and 45.416 million yuan, respectively [2] Leverage Fund Movements - A total of 47 stocks received net purchases from leveraged funds, with notable increases in financing balances for Tailin Micro, Daqian Energy, and Kexing Pharmaceutical, which saw increases of 108 million yuan, 6.698 million yuan, and 6.592 million yuan, respectively [2] - Stocks with significant decreases in financing balances included Rongchang Biological, Sunshine Nuohe, and Liyuanheng, with decreases of 115 million yuan, 21.505 million yuan, and 12.791 million yuan, respectively [2]

Core Viewpoint - The company has announced a share buyback plan with a budget of between 30 million and 60 million RMB, aimed at employee stock ownership plans or equity incentives, with a buyback period from March 17, 2025, to March 16, 2026 [1] Buyback Plan Details - The buyback plan was approved on March 17, 2025, allowing the company to repurchase shares through the Shanghai Stock Exchange [1] - The total amount already repurchased is 4,738.19 million RMB, with a total of 1,269,333 shares bought back, representing 0.64% of the total share capital [2] - The buyback price range has been adjusted, with the maximum price set at 46.83 RMB per share initially, later revised to 46.75 RMB after the annual equity distribution [2] Progress of Buyback - As of June 30, 2025, the company has completed the buyback of 1,269,333 shares at prices ranging from 23.14 RMB to 43.50 RMB per share [2][3] - The total funds used for the buyback, excluding transaction fees, amount to 4,738.19 million RMB [2]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、交易概述 根据公司的整体经营规划，为进一步聚焦生物医药主赛道，降低管理成本， 提高资产运营效率，公司于2025年6月9日召开第二届董事会第二十五次会议、第 二届监事会第二十一次会议审议通过《关于转让全资子公司股权的议案》，公司 将持有的全资子公司深圳同安医药有限公司（以下简称"同安医药"）100%的 股权作价1,500万元转让给广西壮族自治区药物研究所有限公司（以下简称"广 西药研所"）。具体内容详见公司于2025年6月11日在上海证券交易所网站 （www.sse.com.cn）上披露的《关于转让全资子公司股权的公告》（公告编号： 2025-035）。 二、股权转让的进展情况 证券代码：688136 证券简称：科兴制药 公告编号：2025-045 科兴生物制药股份有限公司 关于转让全资子公司股权的进展公告 公司已根据协议的约定办理完成同安医药股权工商变更登记手续，公司不再 持有同安医药股权。 特此公告。 科兴生物制药股份有限公司董事会 2025 年 7 月 3 日 1 根 ...

| 回购方案首次披露日 | 2025/3/19 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 2025 3 3 | 月 | 17 | 日~2026 | 年 | 月 | 16 | 日 | | 预计回购金额 | 3,000万元~6,000万元 | | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | | 累计已回购股数 | 1,269,333股 | | | | | | | | | 累计已回购股数占总股本比例 | 0.64% | | | | | | | | | 累计已回购金额 | 4,738.19万元 | | | | | | | | | 实际回购价格区间 | 23.14元/股~43.50元/股 | | | | | | | | 一、回购股份的基本情况 科兴生物制药股份有限公司（以下简称"公司"）于 2025 年 3 月 17 日召开第 ...

Core Viewpoint - The company, Anglikon, has recently gained significant attention in the market due to its innovative drug business, particularly the ALK-N001 project, which is currently in Phase I clinical trials and received approval in April 2025 [2][3]. Group 1: Company Performance and Market Reaction - Anglikon’s stock price reached a historical high, closing at 40.82 yuan per share, with a trading volume of 6.18 billion yuan and a market capitalization of 82.35 billion yuan [3]. - The company has experienced a decline in net profit, with a 42% drop last year and a 43.63% decrease in the first quarter of this year [3][4]. - Despite the profit decline, the stock has surged by 182% in the first half of the year, with June alone seeing a 146.41% increase, including eight trading halts [4]. Group 2: Research and Development Focus - The company’s increased R&D spending, which reached 231 million yuan (14.99% of revenue), is a key factor in the profit decline, but without this expenditure, net profit would show positive growth [4]. - Anglikon is transitioning towards innovative drug development, collaborating with Shanghai Qinhuali Biotechnology Co., Ltd. to develop the ALK-N001/QHL-1618 product, securing all rights in China [4]. Group 3: Policy Impact on the Industry - Recent favorable policies from the National Healthcare Security Administration and the National Health Commission support the development of innovative drugs, including their inclusion in basic medical insurance and the establishment of a commercial health insurance directory for innovative drugs [3]. - The policies also allow the use of healthcare data for innovative drug research, providing pharmaceutical companies with valuable data services while ensuring data security [3].

【大河财立方 记者 王鑫】7月1日，创新药板块高开高走。 招商证券表示，中国创新药登上全球竞争舞台，技术创新+市场扩容引领创新药产业趋势行情，持续看好后续催 化与兑现。该券商指出，创新药出海，是供给与需求方相互成就的产业逻辑。截至目前，2025年国内创新药项 目已经完成BD项目数量超过80项，分子形式多样广泛。从MNCs引进交易数量及交易金额情况来看，中国成为 增长最快的国家。国内创新药企从2020～2024年首付款金额从5亿美元增长至41亿美元，也侧面印证了国内药企 的全球竞争力。 国联民生证券认为，创新药或将逐步进入兑现期。2025年预计是国内创新药授权出海的重要年份，自2018 年"4+7"集采以后，国内企业纷纷开始从仿制药向创新药转型，至今7年时间，已经陆续进入兑现期。部分先驱 创新药企业有望陆续实现盈亏平衡，利润端转正。 责编:史健 | 审校:张翼鹏 | 审核:李震 | 监审:古筝 截至收盘，Wind创新药指数上涨3.46%。从个股来看，前沿生物涨停，舒泰神、科兴制药涨逾15%，荣昌生物、 微芯生物涨超10%，华纳药厂、泽璟制药、千红制药等涨幅居前。 | 序号 名称 | | 现价 | 涨跌幅 ▼ | ...

Group 1 - The weight loss drug concept increased by 2.51%, ranking 6th among concept sectors, with 46 stocks rising, including Kexing Pharmaceutical, Yipinhong, and Lepu Medical, which rose by 15.62%, 14.72%, and 7.62% respectively [1][2] - The weight loss drug sector saw a net inflow of 576 million yuan, with 24 stocks receiving net inflows, and 8 stocks exceeding 50 million yuan in net inflow, led by Yipinhong with a net inflow of 168 million yuan [2][3] - The top stocks by net inflow rate include Taiankang, Kexing Pharmaceutical, and Yipinhong, with net inflow rates of 20.64%, 14.10%, and 13.25% respectively [3] Group 2 - The concept sectors with the highest daily gains include China Shipbuilding System at 4.90%, Cell Immunotherapy at 3.12%, and Innovative Drugs at 3.01%, while sectors like Electronic ID and Digital Currency experienced declines of -2.52% and -2.40% respectively [2] - The weight loss drug sector's performance is notable among other sectors, indicating a growing interest and investment in this area [1][2]